Intercept Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Intercept Pharmaceuticals

02/08/2023 14:32

* Intercept Pharmaceuticals Inc  ICPT.OQ  reported a
quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
June. The mean expectation of fifteen analysts for the quarter
was for a loss of 51 cents per share.
    * Revenue rose 16.7% to $83.72 million from a year ago;
analysts
expected $79.57 million. 
    * Intercept Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 14 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Intercept Pharmaceuticals Inc shares had fallen by 5.1%
this
quarter and lost 15.1% so far this year.
    * The company reported a quarterly loss of $5.86 million.
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $14.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 2 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.51          -0.14          Beat
 Mar. 31 2023      -0.65          -0.77          Missed
 Dec. 31 2022      -0.16          -0.50          Missed
 Sep. 30 2022      4.61           7.80           Beat